Lessons Learned on Commercializing an Allogeneic T Cell Therapy

Bringing an allogeneic cell therapy from development toward commercialization requires more than scientific innovation. It takes a purpose-built GMP facility, strong quality systems, reliable supply chains, adaptable digital tools, regulatory readiness, and a resilient team prepared to adapt to changing conditions. This webinar will share lessons from our team’s journey to prepare our Thousand Oaks, California, GMP cell therapy facility to advance allogeneic cell therapy commercialization, while navigating challenges shaped by COVID-19, BLA program needs, and the transition to FUJIFILM Biotechnologies California, Inc. as a CDMO.

Attendees will gain insight into:

• Balancing adaptability with compliance and scalability
• Building resilience through quality systems, digital tools, and cross-functional collaboration
• Facility and operational readiness for cell therapy manufacturing that meets global regulatory requirements
• Preparing for multi-product manufacturing environments
• Applying lessons learned to advance patient-focused cell therapy programs